Saturday 17 October 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024. In the quarter to June 2026, revenue grew 42.9%, EPS fell 2,827.3%, free cash flow fell 399.4% and total debt rose 201.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.04
0.15
−4.70%
Follow MNKD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 255.41 | 52.54 |
+8 more quarters Free account |
P/S ratio |
3.35 | 2.09 | 4.97 | 5.25 | |
P/FCF ratio |
0.00 | 57.43 | 126.60 | 37.97 | |
P/Operating CF |
(71.70) | (140.77) | (217.76) | 69.69 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.14 | 2.89 | 5.79 | 5.10 | |
EV/EBITDA |
51.74 | 32.02 | 38.89 | 19.34 | |
EV/Operating CF |
(202.15) | 54.15 | 110.64 | 32.76 | |
EV/FCF |
(89.78) | 79.33 | 147.54 | 36.89 | |
Quick Ratio |
1.08 | 1.20 | 1.23 | 2.54 | |
Current Ratio |
1.72 | 1.87 | 1.70 | 3.29 | |
Net Debt/EBITDA |
45.02 | 50.54 | (95.76) | (2.14) | |
Debt/Assets |
57.64% | 56.68% | 57.82% | 43.11% | |
Debt/Equity |
(6.28) | (7.13) | (8.98) | (4.79) | |
Asset Turnover |
0.69 | 0.63 | 0.59 | 0.65 | |
Operating CF/Net income |
0.97 | 0.32 | 0.50 | 2.96 | |
Capex/Depreciation |
(0.70) | (0.26) | (0.42) | (0.38) | |
Interest Coverage |
(0.02) | (0.13) | (0.55) | 2.58 | |
Research and Development Expense of Revenue |
16.46% | 19.11% | 24.64% | 17.12% | |
Selling, General and Administrative Expense of Revenue |
53.31% | 59.98% | 52.17% | 35.42% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.09 | 0.01 | |
Share Based Compensation of Revenue |
9.35% | 7.16% | 14.67% | (6.25%) | |
Graham Net Nets |
(0.42) | (0.73) | (0.32) | (0.11) | |
Graham Number |
0.80 | 0.54 | 0.00 | 0.00 | |
Earnings Yield |
(3.05%) | (2.77%) | 0.39% | 1.90% | |
Free Cash Flow Yield |
(1.38%) | 1.74% | 0.79% | 2.63% | |
Revenue per Share |
0.35 | 0.29 | 0.37 | 0.27 | |
Operating CF per Share |
(0.06) | (0.02) | (0.03) | 0.08 | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.02) | (0.03) | 0.07 | |
Cash per Share |
0.36 | 0.43 | 0.56 | 0.85 | |
Shareholders Equity per Share |
(0.22) | (0.19) | (0.17) | (0.15) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.22) | (0.19) | (0.17) | (0.15) | |
Free Cash Flow |
(23.45) | (7.24) | (9.95) | 22.52 | |
Working Capital |
102.81 | 116.60 | 120.55 | 249.71 | |
Capital Expenditures |
(5.08) | (1.88) | (1.99) | (1.12) | |
Net Current Asset Value |
(553.79) | (552.44) | (551.62) | (180.35) | |
EV/EBIT |
177.12 | 70.30 | 52.05 | 21.93 | |
Capex to Sales |
0.05 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
143.29 | 50.89 | 44.66 | 22.57 | |
| Other line items | |||||
Average Receivables |
35.17 | 28.52 | 25.09 | 17.78 | |
Average Payables |
10.65 | 10.59 | 7.91 | 6.86 | |
Average Inventory |
36.46 | 39.03 | 31.60 | 26.82 | |
Average Assets |
572.00 | 577.27 | 593.01 | 479.42 | |
Average Common Equity |
(61.12) | (58.91) | (64.92) | (127.24) |
Columns are period end dates